Faculty Information - KISHI Takayuki

■ Published papers

1.	Original article	Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis 2020/07/01
2.	Original article	Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis 2019/06/12
3.	Original article	Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies are Associated with DRB1*07:01 and Severe Myositis in Pediatric Myositis Patients. 2017/07
4.	Original article	The evaluation of gene polymorphisms associated with autoinflammatory syndrome in patients with palindromic rheumatism complicated by intermittent hydrarthrosis 2020/03
5.	Original article	Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. 2018/05
6.	Original article	Clinical analysis of 50 children with juvenile dermatomyositis. 2013/03
7.	Original article	Childhood-Onset Anti-Ku Antibody-Positive Generalized Morphea with Polymyositis: A Japanese Case Study. 2015/09
8.	Original article	Evaluation of Medication Withdrawal in Patients with Non-systemic Juvenile Idiopathic Arthritis in Japan Using a Web-based Survey. 2024/03/05
9.	Original article	Survey of diversity awareness and environment among members of the Pediatric Rheumatology Association of Japan. 2023/10
10.	Original article	Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. 2022/08
11.	Original article	Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties. 2022/04
12.	Original article	Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. 2021/05
13.	Original article	Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. 2021/04
14.	Original article	Updated version of Japanese Childhood Health Assessment Questionnaire (CHAQ) 2020/09
15.	Original article	Medications received by patients with juvenile dermatomyositis. 2018/12
16.	Original article	Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. 2018/11
17.	Case report	Systemic lupus erythematosus associated with RASopathy 2017/07
18.	Original article	A Nationwide Survey of Pediatric Acquired Demyelinating Syndromes in Japan. 2016/11
19.	Case report	Childhood-onset anti-Ku antibody-positive generalized morphea with polymyositis: A Japanese case study 2015
20.	Original article	Long-term outcome of 114 adult JIA patients in a non-pediatric rheumatology institute in Japan. 2014/07
21.	Original article	Extremely low-dose ACTH step-up protocol for West syndrome: Maximum therapeutic effect with minimal side effects 2006/01
22.	Original article	Extremely low-dose ACTH step-up protocol for West syndrome:Maximum therapeutic effect with minimal side effects 2006
Display 5 items
Display all(22)

■ Academic conference presentation

1.	A 7-year-old girl diagnosed with myalgia due to human parechovirus type3 from severe leg pain （Poster notice，General） 2025/04/19
2.	current situation and issues of developmental outpatient care at our hospital （Poster notice，General） 2025/04/19
3.	Social Media Addiction and the Risk of Substance Abuse in Adolescents with Chronic Illness : Report of Two Patients （Poster notice，General） 2025/04/19
4.	Juvenile Dermatomyositis After COVID-19 Infection （Speech，Special/Invited Lecture） 2024/11/21
5.	Treatment of Anti-MDA5 Juvenile Dermatomyositis （Speech，Panelist at Symposium/Workshop (Appointed)） 2024/11/17
6.	Considerations of using the guidelines in the clinical practice of juvenile dermatomyositis （Speech，Panelist at Symposium/Workshop (Appointed)） 2024/05/31
7.	Juvenile Dermatomyositis with Interstitial Lung Disease after COVID-19: A Case Report. （Poster notice，General） 2024/03/15
8.	Medication usage and outcomes in jDM （Speech，General） 2019/03/28
9.	Factors associated with corticosteroid discontinuation, complete clinical response and remission in patients with juvenile dermatomyositis （Speech，General） 2018/10/23
10.	Early treatment with intravenous pulse methylprednisolone of methotrexate is associated with decreased medication requirements at 12 and 24months in patients with juvenile dermatomyositis: a propensity score analysis （Speech，General） 2018/10/21
11.	Circulating Endothelial Calls and Endothelial Activation Markers Correlate with Disease Activity in Juvenile Dermatomyositis. （Speech，Panelist at Symposium/Workshop (Appointed)） 2018/04/27
12.	Distinguishing Features of Clinically Hypomyopathic and Amyopathic Juvenile Dermatomyositis(CAJDM) from Juvenile Dermatomyositis(JDM) （Speech，Panelist at Symposium/Workshop (Appointed)） 2018/04/27
13.	Predictors of Clinical Outcomes in Patients with Juvenile Dermatomyositis. （Speech，Panelist at Symposium/Workshop (Appointed)） 2018/04/27
14.	Characteristics of infants born to mothers with autoimmune disorders （Poster notice，General） 2014/09/20
15.	Prevalence of polymorphisms of the genes responsible for auto-inflammatory diseases among 202 patients with recurrent fever in a rheumatology ins-tute in Japan （Poster notice，General） 2014/09/19
16.	Safety and efficacy of adalimumab in a girl with refractory intestinal Behcet's disease （Poster notice，General） 2014/09/19
17.	Cytokine increase in the cerebrospinal fluid as the underlying immunological mechanism in a case of Dravet syndrome with acute encephalopathy （Poster notice，General） 2014/02/21
18.	A case of chylothorax, treated effectively with surgical treatment （Poster notice，General） 2011/08/14
19.	Selection of isotonic saline as initial parenteral fluid therapy for children with either of high fever, vomiting and dyspnea （Speech，General） 2011/06/02
20.	Two Japanese girls with juvenile-onset tumefactive multiple sclerosis （Poster notice，General） 2011/05/13
Display 5 items
Display all(20)

■ Qualifications & licenses

1.

2021/12

Infection control doctor

■ Research grants & projects

1.	2017/06～2017/09	Heterogeneity of Juvenile Myositis, with a Focus on Therapies and Responses. (Key Word : )
2.	2015/06～2017/05	Responses to Treatment in the Juvenile Idiopathic Inflammatory Myopathies. (Key Word : )

■ Conference activities & talks

1.

2022/05/18

Management of MDA-5 antibody-positive juvenile dermatomyositis associated interstitial lung disease

■ Awards & honors

1.

2018/04

The 62nd Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology(JCR 2018) Excellent Abstract Award: JCR 2018

■ Education

1.	2012/10/19 Degree Acquisition	Tokyo Women's Medical University,
2.	1997/04～2003/03	Nihon University, Graduated